Literature DB >> 24418806

Reducing infection rates after prostate biopsy.

Florian M E Wagenlehner1, Adrian Pilatz1, Przemyslaw Waliszewski1, Wolfgang Weidner1, Truls E Bjerklund Johansen2.   

Abstract

Over the years, prostate biopsy has become the gold-standard technique for diagnosing prostate carcinoma. Worldwide, several million prostate biopsies are performed every year, most commonly using the transrectal approach. Preoperative antibiotic prophylaxis with fluoroquinolones has been shown to be effective for reducing infection rates. However, in recent years, an increase in febrile infection rates after transrectal prostate biopsy (from 1% to 4%) has been reported in retrospective and prospective studies. The predominant risk factor for infection seems to be the presence of fluoroquinolone-resistant bacteria in faeces. Patients at risk of fluoroquinolone resistance should receive carefully selected antibiotics at sufficient concentrations to be effective. Targeted prophylaxis after rectal flora swabbing has been shown to be efficacious compared with empirical antibiotic prophylaxis. Several forms of bowel preparations are under investigation, although none have yet been shown to significantly reduce infection rates. Perineal prostate biopsy is currently being evaluated as a strategy for preventing the inoculation of rectal flora, but limited data support this approach at present.

Entities:  

Mesh:

Year:  2014        PMID: 24418806     DOI: 10.1038/nrurol.2013.322

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  58 in total

Review 1.  Antibiotic therapy--rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue.

Authors:  Kurt G Naber; Fritz Sörgel
Journal:  Andrologia       Date:  2003-10       Impact factor: 2.775

2.  Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use.

Authors:  Stacy Loeb
Journal:  BJU Int       Date:  2011-10-31       Impact factor: 5.588

3.  Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors.

Authors:  Sandra Lindstedt; Ulla Lindström; Eva Ljunggren; Björn Wullt; Magnus Grabe
Journal:  Eur Urol       Date:  2006-05-16       Impact factor: 20.096

4.  Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary?

Authors:  Jordi Puig; Anna Darnell; Patricia Bermúdez; Antoni Malet; Guadalupe Serrate; Marisa Baré; Joan Prats
Journal:  Eur Radiol       Date:  2006-01-04       Impact factor: 5.315

5.  Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-acquired bacteraemia due to urinary tract infection.

Authors:  G Elhanan; M Sarhat; R Raz
Journal:  J Infect       Date:  1997-11       Impact factor: 6.072

6.  Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation.

Authors:  Kogenta Nakamura; Kazuro Ikawa; Yoshiaki Yamada; Maki Arakawa; Kenji Zennami; Genya Nishikawa; Kayo Ikeda; Norifumi Morikawa; Nobuaki Honda
Journal:  J Chemother       Date:  2012-02       Impact factor: 1.714

7.  Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy.

Authors:  Michael A Liss; Alexandra Chang; Rosanne Santos; Amy Nakama-Peeples; Ellena M Peterson; Kathryn Osann; John Billimek; Richard J Szabo; Atreya Dash
Journal:  J Urol       Date:  2011-02-22       Impact factor: 7.450

8.  Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare.

Authors:  Stacy Loeb; H Ballentine Carter; Sonja I Berndt; Winnie Ricker; Edward M Schaeffer
Journal:  J Urol       Date:  2012-10-09       Impact factor: 7.450

9.  The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate.

Authors:  Sakir Ongün; Güven Aslan; Vildan Avkan-Oguz
Journal:  Urol Int       Date:  2012-09-22       Impact factor: 2.089

10.  Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007.

Authors:  Majdi N Al-Hasan; Brian D Lahr; Jeanette E Eckel-Passow; Larry M Baddour
Journal:  J Antimicrob Chemother       Date:  2009-05-12       Impact factor: 5.790

View more
  23 in total

Review 1.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

Review 2.  [Prostate biopsy: Procedure in the clinical routine].

Authors:  T Enzmann; T Tokas; K Korte; M Ritter; P Hammerer; L Franzaring; H Heynemann; H-W Gottfried; H Bertermann; M Meyer-Schwickerath; B Wirth; A Pelzer; T Loch
Journal:  Urologe A       Date:  2015-12       Impact factor: 0.639

Review 3.  [Biopsies of the kidney, prostate and urinary bladder].

Authors:  F M E Wagenlehner; W Weidner; T Diemer; B Altinkilic
Journal:  Urologe A       Date:  2014-05       Impact factor: 0.639

4.  Transrectal Ultrasound-guided Versus Transperineal Mapping Prostate Biopsy: Complication Comparison.

Authors:  Vassilios M Skouteris; E David Crawford; Vladimir Mouraviev; Paul Arangua; Marios Panagiotis Metsinis; Michael Skouteris; George Zacharopoulos; Nelson N Stone
Journal:  Rev Urol       Date:  2018

Review 5.  Cutting to the Core of the Issue: Emerging Strategies To Reduce Prostate Biopsy-Related Infections.

Authors:  Robin R Chamberland
Journal:  J Clin Microbiol       Date:  2016-05-04       Impact factor: 5.948

6.  Planning for the post-antibiotic era - why we must avoid TRUS-guided biopsy sampling.

Authors:  Declan G Murphy; Jeremy P Grummet
Journal:  Nat Rev Urol       Date:  2016-09-20       Impact factor: 14.432

7.  Rectal E. coli above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy.

Authors:  Inari Kalalahti; Kaisa Huotari; Kanerva Lahdensuo; Eveliina Tarkka; Henrikki Santti; Antti Rannikko; Anu Pätäri-Sampo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-02       Impact factor: 3.267

8.  TRUS-guided transperineal prostate 12+X core biopsy with template for the diagnosis of prostate cancer.

Authors:  Gang Guo; Yong Xu; Xu Zhang
Journal:  Oncol Lett       Date:  2017-04-20       Impact factor: 2.967

9.  [Value of perineal HistoScanning™ template-guided prostate biopsy].

Authors:  M F Hamann; C Hamann; D Olzem; A Trettel; K P Juenemann; C M Naumann
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

10.  Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005-2013: a population-based analysis.

Authors:  K Lahdensuo; A Rannikko; V-J Anttila; A Erickson; A Pätäri-Sampo; M Rautio; H Santti; E Tarkka; M Vaara; K Huotari
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-08-16       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.